Rosie Z. Yu

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary et al. · The Lancet · 2016 · 730 citations

Dose-ranging Trials, Pharmacology, Hyperlipidemia +7

Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides

Mark J. Graham, Richard Lee, Teresa Brandt et al. · New England Journal of Medicine · 2017 · 567 citations · Full text

Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

John J.P. Kastelein, Mark K. Wedel, Brenda F. Baker et al. · Circulation · 2006 · 356 citations · Full text

Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis

Hong Zhang, Jesse D. Cook, Jeffrey C. Nickel et al. · Nature Biotechnology · 2000 · 271 citations

Liver Fibrosis, Immunology, Cell Death +18

Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100

Rosie Z. Yu, Tae‐Won Kim, An Hong et al. · Drug Metabolism and Disposition · 2006 · 236 citations